Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial of nivolumab and ipilimumab for advanced kidney cancer (CheckMate 214)
Coronavirus and cancer
We know it’s a worrying time for people with cancer, we have information to help. If you have symptoms of cancer contact your doctor.
This trial compared nivolumab and ipilimumab with a standard treatment called sunitinib for kidney cancer.
It was for people with a type of kidney cancer called renal cell cancer that had grown outside the kidney or spread to another part of the body.
More about this trial
- find out how well nivolumab and ipilimumab worked compared to sunitinib for renal cell cancer
- learn more about the side effects
- find out more about quality of life
Summary of results
- 422 people had a high chance
- 425 people had a medium chance
- 249 people had a low chance
The researchers looked at how long people lived before the cancer started to grow again. This is called progression free survival. This was:
- nearly 12 months in people who had ipilimumab and nivolumab
- just over 8 months in people who had sunitinib
- went away completely in 40 people
- went away a little bit in 137 people
- stayed the same in 133 people
- got worse in 83 people
- went away completely in 5 people
- went away a little bit in 107 people
- stayed the same in 188 people
- got worse in 72 people
- over 7 out of 10 people (75%) who had ipilimumab and nivolumab
- 6 out of 10 people (60%) who had sunitinib
- fatigue (tiredness)
- feeling or being sick
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor Robert Hawkins
Experimental Cancer Medicine Centre (ECMC)